Genetic Mutation Analysis In A VHL Population
18 Years
N/A
Both
Kidney Cancer, Von Hippel-lindau Syndrome
Trial Information
Genetic Mutation Analysis In A VHL Population
OBJECTIVES:
- Obtain laboratory identification and confirmation of research results for gene
mutations in participants previously enrolled in NCI-99-C-0053 who have von
Hippel-Lindau (VHL) syndrome or who are at risk for VHL syndrome.
- Determine genotype status in these participants.
OUTLINE: Participants submit a blood or buccal sample for genetic mutation analysis.
Participants may receive genetic counseling and/or the results of genetic testing, if
desired.
PROJECTED ACCRUAL: A maximum of 260 participants will be accrued for this study.
Inclusion Criteria
DISEASE CHARACTERISTICS:
- Prior enrollment in the von Hippel-Lindau (VHL) Syndrome Epidemiology Study
NCI-99-C-0053
- Meets 1 of the following criteria:
- Diagnosis of VHL syndrome
- At risk of VHL syndrome
- Family member of patient with VHL syndrome
- VHL syndrome genotype is not known
PATIENT CHARACTERISTICS:
Age
- Adult
Performance status
- Not specified
Life expectancy
- Not specified
Hematopoietic
- Not specified
Hepatic
- Not specified
Renal
- Not specified
PRIOR CONCURRENT THERAPY:
Biologic therapy
- Not specified
Chemotherapy
- Not specified
Endocrine therapy
- Not specified
Radiotherapy
- Not specified
Surgery
- Not specified
Type of Study:
Observational
Study Design:
N/A
Principal Investigator
William M. Linehan, MD
Investigator Role:
Study Chair
Investigator Affiliation:
NCI - Urologic Oncology Branch
Authority:
United States: Federal Government
Study ID:
030148
NCT ID:
NCT00075348
Start Date:
December 2003
Completion Date:
December 2008
Related Keywords:
- Kidney Cancer
- Von Hippel-lindau Syndrome
- renal cell carcinoma
- von Hippel-Lindau syndrome
- Carcinoma, Renal Cell
- Kidney Neoplasms
- Von Hippel-Lindau Disease
Name | Location |
|---|---|
| Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office | Bethesda, Maryland 20892-1182 |
